{
  "slug": "nad-boosters-human-function",
  "round": 2,
  "date": "2026-10-14",
  "authoring_model": "Sol 6.1",
  "reviewer": "Claude Opus 5.5 (Anthropic)",
  "canonical_path": "hsef_v53_traffic_ranks_21_22_2026-10-13/nad-boosters-human-function/nad-boosters-human-function.review.md",
  "level_before": "Δ",
  "level_after": "Δ",
  "confidence_before": "Low",
  "confidence_after": "Low",
  "role_before": "reinforcing / stabilizing factor",
  "role_after": "reinforcing / stabilizing factor",
  "msd_before": {
    "momentum": "Mechanistic only",
    "stability": "Stable",
    "divergence": "Contested"
  },
  "msd_after": {
    "momentum": "Mechanistic only",
    "stability": "Stable",
    "divergence": "Contested"
  },
  "counts": {
    "critical": 0,
    "major": 3,
    "minor": 3,
    "editorial": 1,
    "total": 7
  },
  "pmids_checked": 72,
  "pmids_in_references": 70,
  "pmids_failed": 0,
  "claims_spot_checked": 14,
  "claims_misattributed": 0,
  "validator": "PASS - 0 fail, 0 warn, 31 pass",
  "findings": [
    {
      "id": "A1",
      "severity": "Major",
      "type": "internal consistency",
      "location": "Decisive-perturbation inventory and causal tally; scorecard causal_tally_audit",
      "original": "Tally: 0 positive qualifying study units across scoped subclaims; 54 screened discriminating contrast units.",
      "corrected": "Tally: 1 positive qualifying study unit across scoped subclaims (the twelve-week randomized gait-time contrast supporting SC2); 54 screened discriminating contrast units.",
      "evidence": "Same paragraph states one positive qualifying source is counted for the primary gate; SC2 records a positive full-scope result at Δ; Δ requires at least one field-valid causal perturbation."
    },
    {
      "id": "A2",
      "severity": "Major",
      "type": "internal consistency",
      "location": "Decisive-perturbation inventory, closing paragraph",
      "original": "No positive field-valid crossing was verified for the registered causal scope in this bounded audit.",
      "corrected": "Outside the primary SC2 functional gate, no positive field-valid crossing was verified for the SC1 exposure-marker, SC3 longevity or SC4 equivalence scopes in this bounded audit.",
      "evidence": "Contradicted the SC2 upward-ladder entry (satisfied: yes) and the assigned Δ headline."
    },
    {
      "id": "A3",
      "severity": "Minor",
      "type": "scoring logic (required artifact)",
      "location": "Final score, causal direction and M/S/D; scorecard extended_scoring_MSD.divergence",
      "original": "Divergence: Contested. No invented numerical belief gap is inferred from supplement marketing or a provider strength label.",
      "corrected": "Divergence rationale now names the split it rests on (promotional framing above the assessed level, trial literature at or below it); value unchanged.",
      "evidence": "Framework requires a checkable artifact for Divergence; the prior rationale named no split."
    },
    {
      "id": "A4",
      "severity": "Minor",
      "type": "rendering defect / citation field",
      "location": "REFERENCE 33 (Wang CP et al., 2014, J Endocrinol Diabetes Obes)",
      "original": "DOI: .",
      "corrected": "DOI: none indexed in PubMed.",
      "evidence": "PubMed record 25506599 carries no DOI; the empty field is the known builder defect."
    },
    {
      "id": "A5",
      "severity": "Minor",
      "type": "rendering defect",
      "location": "throughout, approximately 50 sites",
      "original": "for24weeks / age65-75 / all60 / week6 removes22of42 / 1250mgNMN / the70PMID-based / one-sided90% / published25September2026 / DOI10.1038 / returned0 / identify42randomized / leaving10per arm / ordinary20of42follow-up / the24-week250mgolder-diabetes / cap4 / cap2 / reachesZeta / retainDelta / Nominal Pvalues / ErratumIn:",
      "corrected": "spaces restored around numerals, symbols and ladder letters; no value, unit or identifier altered",
      "evidence": "Known upstream rendering defect (missing spaces around numerals)."
    },
    {
      "id": "A6",
      "severity": "Editorial",
      "type": "rendering defect",
      "location": "throughout, 10 sites",
      "original": "doubled field-separator full stops; MIB626",
      "corrected": "single full stop; MIB-626",
      "evidence": "Template concatenation artifact; formulation name normalised to the cited product name."
    },
    {
      "id": "A7",
      "severity": "Major",
      "type": "rendering defect / misstatement",
      "location": "AT A GLANCE, 'Best-supported rival' line",
      "original": "Best-supported rival: NMN restores a functionally limiting NAD pathway.",
      "corrected": "Best-supported rival: Exposure and functional response are partly dissociated (Δ) — the highest-ranked model that is not the nominal; the nominal model, NMN restoring a functionally limiting NAD pathway, ranks second.",
      "evidence": "Known renderer defect: the field printed competing_models.models_evaluated[0], which in this score card is the nominal model (is_nominal true, rank_in_tournament 2) rather than the rank-1 rival. As written it told the reader that the leading alternative explanation was the hypothesis itself. Score card rank and nominal flags are correct and were not changed."
    }
  ],
  "rejected_findings": [
    "Citation years differing by one from PubMed e-pub dates: refs 5 (36443648), 8 (37994989), 23 (28681986), 34 (36482258), 45 (36515353), 47 (37899683), 63 (39363095), 64 (30548390). House convention.",
    "PubMed titles dropping superscripts/italics (NAD+, beta-NMN, H2O2, RYR1): field artifact, not a citation error.",
    "DOI-only Igarashi 2026 npj Aging source: PubMed search on 2026-10-14 still returns no record; separately displayed non-counted handling with no invented PMID is correct.",
    "Momentum 'Mechanistic only': required artifact present (UMIN000054187 plus ongoing pharmacodynamic work); does not claim decisive work underway.",
    "Delta for SC2 resting on a randomized secondary gait endpoint: argued against and retained; the registered gate admits measured gait and a trial-primary requirement would be a post hoc rule.",
    "Aggregation rule primary-subclaim (SC2) applied as written; scope-matched would also return Delta.",
    "No collective-author rendering defect present in this reference list.",
    "Confidence band Low verified against the framework's confidence text rather than access depth: the crossing rests on one secondary endpoint in one trial, so neither Moderate nor High is reachable.",
    "No false-approval boilerplate and no false provenance clause present; no earlier adversarial approval is asserted."
  ],
  "residual_limitations": "Crossing rests on one secondary endpoint in one trial with no stated familywise correction and two missing placebo week-12 observations; the second supporting trial had allocation disrupted by a supplier cross-switch; only 3 of 70 sources examined beyond abstract depth.",
  "propagation": {
    "propagate_to": [
      "hsef_v53_topical_all_22_2026-10-13/cycles/hsef_v53_traffic_ranks_21_22_2026-10-13_share/nad-boosters-human-function/nad-boosters-human-function.review.md",
      "hsef_v53_traffic_ranks_21_22_2026-10-13_share/nad-boosters-human-function/nad-boosters-human-function.review.md"
    ],
    "divergent_copies": []
  },
  "approval": "Approved as revised. — Claude Opus 5.5 (Anthropic), 2026-10-14."
}